Clinical Trials
170
Active:13
Completed:88
Trial Phases
4 Phases
Phase 1:105
Phase 2:27
Phase 3:31
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (167 trials with phase data)β’ Click on a phase to view related trials
Phase 1
105 (62.9%)Phase 3
31 (18.6%)Phase 2
27 (16.2%)Not Applicable
4 (2.4%)Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT07199010
- Locations
- π¨π³
Shanghai East Hospital (The East Hospital Affiliated to Tongji University), Shanghai, Shanghai Municipality, China
A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors
Not Applicable
Not yet recruiting
- Conditions
- EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
- Interventions
- Drug: IBI363+IBI305
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT07124793
- Locations
- π¨π³
Tongji Hospital affiliated to Tongji Medical College HUST, Wuhan, Hubei, China
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Not Applicable
Recruiting
- Conditions
- Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 170
- Registration Number
- NCT07122687
- Locations
- π¨π³
Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 111
- Registration Number
- NCT07113262
- Locations
- π¨π³
The First Affiliated Hospital of Medical University, Shenyang, Liaoning, China
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 201
- Registration Number
- NCT07066098
- Locations
- π¨π³
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 34
- Next
News
No news found